The European Commission (EC) through the EU funding programme for research and innovation 'Horizon 2020' has committed €15 million and the Department of Biotechnology (DBT), Government of India, agreed to match that amount. This call aims at further advancing the next generation influenza vaccine candidate(s) with improved efficacy and safety, duration of immunity, and reactivity against an increased breadth of influenza strains.
In total, funding of €30 million will thus be available. Information and project preparation events will be organised in four cities (New Delhi, Hyderabad, Bangalore and Pune) in India at the end of August 2018.
These events target potential applicants to the EU-India call on Next Generation Influenza Vaccine for joint project proposals.
It will offer an exceptional opportunity to all stakeholders from lab to market: research, pre-clinical trials and vaccine developers from Europe and India.